



CODEN [USA]: IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**Available online at: <http://www.iajps.com>

Review Article

**TELMISARTAN EFFECT IN HYPERTENSION ASSOCIATED
WITH DYSLIPIDEMIA**Araveti Lokesh¹, Somana boina Padmakar^{1*}, K. Sujan kumar², S. Parveen³.^{1,2}Pharm-D, P. Rami Reddy Memorial College of Pharmacy [PRRMCP], Kadapa, Andhra Pradesh, India-516003.³Assitant Professor, P. Rami Reddy Memorial College of Pharmacy [PRRMCP], Kadapa, Andhra Pradesh, India-516003.**Abstract:**

Hypertension and dyslipidemia are two major risk factors for cardiovascular diseases and commonly occur together. Dyslipidemia is a primary, widely established as an independent major risk factor for coronary heart disease. Management of dyslipidemia in hypertension patients significantly decreases the total cardiovascular risk. Peroxisome proliferator-activated receptors [PPARs] belong to the nuclear family of ligand activated transcriptional factors and comprise three different isoforms, PPAR- α , PPAR- β/δ , and PPAR- γ . The main role of PPARs is to regulate the expression of genes involved in lipid and glucose metabolism. Several studies have demonstrated that PPAR agonists improve dyslipidemia and glucose control in animals, supporting their potential as a promising therapeutic option to treat diabetes and dyslipidemia. PPAR- γ , the best characterized of the PPARs, plays a crucial role in adipogenesis and insulin sensitization. Telmisartan, an angiotensin receptor blocker [ARB] that is highly selective for AT1 receptor has been found to be a PPAR- α agonist and a selective PPAR-G modulator. This unique action of telmisartan on PPAR leads to favourable effects on lipid and carbohydrates metabolism which is independent of BP lowering effect. This provides additional benefit in treatment of dyslipidemia.

Keywords: *Telmisartan, Hypertension, Dyslipidemia, PPAR.***Corresponding author:****Somana boina Padmakar,**

Pharm-d Internship

P. Rami Reddy Memorial College of Pharmacy

Kadapa

slrdlfamily@gmail.com

QR code



Please cite this article in press as Somana boina Padmakar *et al.*, *Telmisartan Effect in Hypertension Associated With Dyslipidemia*, *Indo Am. J. P. Sci.*, 2017; 4(12).

INTRODUCTION:**Hypertension**

Hypertension is defined by persistent elevation of arterial blood pressure [BP]. Patients with diastolic blood pressure [DBP] values <90 mm Hg and systolic blood pressure [SBP] values ≥ 140 mm Hg have isolated systolic hypertension.[1]

Hypertension remains the most prevalent cardiovascular disease [CVD] risk factor and is present in ever-growing numbers worldwide.[2,3] In the United States hypertension affects over 30% of adults or approximately 76,400,000 [2008 data] men and women age 20 years. Data from the National Health and Nutrition Examination Survey indicate that approximately 8% of adults in the United States have undiagnosed hypertension, and of those diagnosed only three-quarters use antihypertensive medications. Among those taking medication, blood pressure [BP] is controlled in only half.[4] The societal and financial burden of hypertension is not likely to reverse soon as projections suggest a 10% increase in hypertension prevalence by the year 2030.[5] These statistics are especially troubling when one considers the consequences of hypertension; elevated BP [140/90 mmHg] precedes myocardial infarction [MI], stroke, or congestive heart failure in 69% of cases.[6]

In hypertensive individuals, there is a high prevalence of decreased level of high density lipoprotein [HDL], increased total cholesterol and elevated triglyceride [TG] levels as compared to normotensive individuals.[7] Hypertension is a common cardiovascular disease and coexists with conditions like dyslipidemia and ischemic heart disease. Elevated total cholesterol [TC] levels increase the risk of cardiovascular disease associated with hypertension and dyslipidaemia. When these two conditions coexist, it demands a strict emphasis on dietary and pharmacological therapy to achieve control on both successfully. Contrary to the goal, it is reported that only in 32% of hypertensive patients; lipid profile is improved, while this percentage falls to eleven for control of both blood pressures [BP] and lipids.[8]

DYSLIPIDEMIA:

Disorders of lipoprotein metabolism together with high fat diets, obesity and physical inactivity have all contributed to the current epidemic of atherosclerotic disease seen in developed countries. Disorders of lipoprotein metabolism that result in elevated serum concentrations of total cholesterol [TC] and low-density lipoprotein cholesterol [LDL-C] increase the risk of an individual developing cardiovascular

disease [CVD]. In contrast, high-density lipoprotein cholesterol [HDL-C] confers protection against CVD, with the risk reducing as HDL-C increases. It is, therefore, clear that the term hyperlipidaemia, which was formerly used to describe disorders of lipoprotein metabolism, is inappropriate. It is more appropriate to use the term dyslipidaemia, which encompasses both abnormally high levels of specific lipoproteins, for example, LDL-C, and abnormally low levels of other lipoproteins, for example, HDL-C, as well as disorders in the composition of the various lipoprotein particles. It is particularly appropriate when considering the individual at risk of CVD with a normal or high TC and low HDL-C [total cholesterol:HDL-C ratio].[9]

Up to 60% of the variability in cholesterol fasting lipids may be genetically determined, although expression is often influenced by interaction with environmental factors. The common familial [genetic] disorders can be classified as:

- The primary hypercholesterolaemias such as familial hyper-cholesterolaemias in which LDL-C is raised.
- The primary mixed [combined] hyperlipidaemias in which both LDL-C and triglycerides are raised.
- The primary hypertriglyceridaemias such as type III hyperlipoproteinaemia, familial lipoprotein lipase deficiency and familial apoC-II deficiency.[9]

Hypertension and hyperlipidemia commonly coexist. In hypertensive individuals, there is a high prevalence of decreased level of high density lipoprotein [HDL], increased total cholesterol and elevated triglyceride [TG] levels as compared to normotensive individuals.[10] Elevated total cholesterol [TC] levels increase the risk of cardiovascular disease associated with hypertension and dyslipidaemia. When these two conditions coexist, it demands a strict emphasis on dietary and pharmacological therapy to achieve control on both successfully. Contrary to the goal, it is reported that only in 32 % of hypertensive patients; lipid profile is improved, while this percentage falls to eleven for control of both blood pressures [BP] and lipids.[11] The antihypertensive drugs primarily affect the increased blood pressure without affecting the disordered lipid metabolism that often accompanies hypertension. Angiotensin II receptor blockers [ARBs] are efficient antihypertensive agents that act through inhibition of AT1 receptors.[12]

ANGIOTENSIN II RECEPTOR BLOCKERS

Angiotensin II receptor antagonists [angiotensin receptor blockers [ARBs]] are widely used clinically as antihypertensive agents. In addition to reducing blood pressure [BP], ARBs attenuate cardiovascular risk via suppression of the renin-angiotensin system [RAS] mediated by antagonism of the angiotensin II [AT1] receptor.[13] There are eight ARBs currently on the market for hypertension and in different cardiovascular indications, ie, losartan, valsartan, candesartan, eprosartan, irbesartan, telmisartan, olmesartan, and azilsartan. All ARBs are approved for the treatment of hypertension. In addition, irbesartan and losartan are approved for diabetic nephropathy, losartan is approved for stroke prophylaxis, and valsartan and candesartan are approved for heart failure and to reduce cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction. ARBs also demonstrated effectiveness in preventing atheromas, decreasing endothelial dysfunction, increasing fibrinolysis, reducing proteinuria, and preserving kidney function in diabetic patients.[14]

TELMISARTAN

Telmisartan is licensed for the treatment of essential hypertension. Telmisartan, a nonpeptide AT-II-receptor antagonist, gained FDA approval for use in the treatment of hypertension in 1998. Peak plasma levels are obtained 0.5-1 hour after oral administration, and the plasma $t_{1/2}$ is ~24 hours. Oral bioavailability of ARBs generally is low [$<50\%$, except for irbesartan, with 70% available], and protein binding is high [$>90\%$]. Telmisartan is cleared from the circulation mainly by biliary secretion of intact drug. The plasma clearance of telmisartan is affected by hepatic but not renal insufficiency.[15] The recommended oral dosage of telmisartan is 40-80 mg once daily. When further blood pressure reduction is needed [beyond that achieved with 80 mg/day], the addition of hydrochlorothiazide has been found to produce incremental reductions.[16]

DRUG INTERACTIONS

No interactions with drugs that inhibitor are metabolized by CYP isoenzymes would be expected, given that CYP isoenzymes are not involved in telmisartan's metabolism, with the possible exception of interference with the metabolism of drugs metabolized by CYP2C19. When telmisartan is administered with digoxin, peak and trough plasma concentrations of digoxin are increased 49% and 20%, respectively. When telmisartan is given with

warfarin there is no evidence of any change in the International Normalized Ratio.

ADVERSE EVENTS

The overall frequency of adverse events with telmisartan 20-160 mg/ day was reported to be similar to that with placebo. Rates of upper-respiratory-tract infection [7%], dizziness [5%], back pain [3%], sinusitis [3%], and diarrhea [3%] were similar to the rates for placebo [6%, 6%, 1%, 3%, and 2% respectively]. The rate of cough with telmisartan [15.6%] was comparable to that with placebo [9.6%] and significantly less than with lisinopril [60%].[16]

Numerous studies have demonstrated that the peroxisome proliferator-activated receptor- γ [PPAR- γ] plays an important role in regulating carbohydrate and lipid metabolism and that ligands for PPAR- γ can improve insulin sensitivity, reduce triglyceride levels, and decrease the risk for atherosclerosis.[17]

Peroxisome proliferator-activated receptors [PPAR] are nuclear hormone-activated receptors and transcription factors. To date, three different PPAR subtypes have been cloned and characterized: PPAR- α , PPAR- β and PPAR- γ [18-21]. The ligands for PPAR have been demonstrated to include structurally diverse compounds that vary from industrial chemicals and pharmaceutical drugs to endogenous fatty acids. These ligands can induce enormous molecular and cellular changes, including peroxisome proliferation, adipogenesis, β -oxidation enhancement, and cell-cycle regulation. After a decade of intense study, much has been learned regarding the molecular mechanisms by which PPAR activation results in its biologic consequences. PPAR have been shown to be critical factors in regulating diverse biologic processes, including lipid metabolism, adipogenesis, insulin sensitivity, immune response, and cell growth and differentiation.[18-21] and participate in the pathogenesis of a cluster of human diseases designated the metabolic syndrome, which includes insulin resistance, glucose intolerance, obesity, dyslipidemia, hypertension, atherosclerosis, and micro-albuminuria.[22-24]

Importantly, the fibrate class of PPAR- α agonists including fenofibrate and clofibrate are clinically proven lipid-lowering drugs [25], whereas the thiazolidinedione [TZD] class of PPAR- γ ligands such as rosiglitazone [Avandia] and pioglitazone [Actos] have recently been introduced into clinical practice for treating hyperglycemia and insulin resistance in patients with type 2 diabetes [26].

TISSUE EXPRESSION OF PPAR

In general, PPAR- α is highly expressed in tissues that possess high mitochondrial and β -oxidation activity, including liver, renal cortex, intestine mucosa, and heart. Lower expression of PPAR- α is also observed in several other tissues. PPAR- γ is highly enriched in adipose tissue, but lower expression levels have also been reported in urinary bladder, intestine, kidney, spleen, adrenal, heart, liver, lung, brain, and vasculature. Unlike PPAR- α and PPAR- γ , PPAR- β/δ seems to be ubiquitously expressed at low levels in almost every tissue examined. In the kidney, PPAR- α is highly abundant in the proximal tubules and medullary thick ascending limbs with much lower levels in glomerular mesangial cells [27,28].

MODE OF PPAR ACTION

Upon binding their cognate ligands, the transcriptional activity of PPAR is altered. A conformational change in the PPAR/retinoid X receptor-A [RXR-A] dimer allows the heterodimer to bind to PPAR-response elements [PPRE] to activate gene transcription. PPRE generally consist of a direct repeat of hexameric core recognition elements

spaced by 1 bp [DR1, 5'AGGTCANAGGTCA-3'] located in the promoter regions of target genes [Figure 1] [18]. After activation of the PPAR/RXR heterodimer at the PPRE, the PPAR/RXR-A complex can recruit diverse nuclear receptor co-factors that modulate transcriptional activity of PPAR and RXR-A receptor heterodimer. These coactivators include cAMP response element-binding protein, PPAR- γ coactivators, cAMP response element-binding protein binding protein, and steroid receptor coactivator-1. Co-repressors such as nuclear receptor co-repressor and silencing mediator of retinoid acid and thyroid hormone receptor can modulate the transcriptional activity of PPAR by remodeling chromatin and establishing physical contacts with transcription initiation machinery. Therefore, multiple mechanisms are involved in controlling the transcription of PPAR target genes in a given cell or tissue. The expression level of PPAR receptors, the chemical properties and local concentrations of PPAR-specific ligands, and the availability of these co-factors all contribute to the biologic effect of PPAR activation or inactivation. [20,29].




Fig.1: Mode of PPAR Action

Unlike natural fatty acids, which are good substrates for P-oxidation, substituted fatty acids, which are not a substrate for P-oxidation, are more potent PPAR activators, suggesting that the degree of PPAR activation is inversely correlated with the rate of fatty acid P-degradation. Although these studies demonstrate that exogenous fatty acids activate PPAR, it is not clear whether the active form is the acid or the acyl-CoA thioester, the production of which is controlled by the enzyme acyl-CoA synthetase. These acyl-CoA derivatives are either stored as an intracellular acyl-CoA ester pool complexed with the acyl-CoA binding protein or utilized in various intracellular enzymatic pathways. The direct involvement of acyl-CoA derivatives in intracellular lipid metabolism [in contrast to free fatty acids], together with the finding that xenobiotic peroxisome proliferators also form acyl-CoA esters, suggests that acyl-CoAs may be PPAR activators and/or ligands.[30]

Peroxisome proliferator-induced acyl-CoA synthetase activity generates acyl-CoA esters that are used predominantly for P-oxidation [31,32]. Due to the pronounced increase of peroxisomal P-oxidation, associated with a more moderate induction of mitochondrial P-oxidation, after treatment with peroxisome proliferators, less acyl-CoA esters should be available to be utilized for TG synthesis. A reduction in acetyl-coA carboxylase [33-35] and fatty acid synthase [36] activities will inhibit de novo fatty acid synthesis, further diminishing the intracellular fatty acid levels available for TG synthesis [37]. Moreover, peroxisome proliferators not only increase P-oxidation and decrease TG synthesis [38], but also decrease apoB and VLDL production and secretion [35, 39-40].

Telmisartan acts as a partial PPAR α agonist and induces PPAR α expression. Thus there is induction of hepatic ACSL1 [acyl coA synthetase long chain] and CPT1A [carnitine palmitoyl transferase]. This causes significant decrease of triglyceride level. PPAR α in skeletal muscle is not affected by Telmisartan. Hence the myopathy associated with fibrates is not seen with Telmisartan. Thus PPAR α activation by Telmisartan is liver specific because of its specific pharmacokinetic Profile[41].

DISCUSSION:

Telmisartan is an angiotensin 2 type 1 receptor blocker, originally developed for the treatment of essential hypertension. It was also reported to partially activate the peroxisome proliferator receptor gamma [PPAR- γ] which may improve insulin sensitivity and dysregulation of adipokine

secretion. This activation of Telmisartan through PPAR- γ activation has additional benefit in the treatment of essential hypertension with dyslipidemia. Many animal studies have demonstrated the beneficial effects of telmisartan on obesity, accumulation of visceral adipose tissues, insulin sensitivity and fatty liver.

PPARs are ligand activated transcription factors belonging to the super family of nuclear receptors. PPAR γ is abundantly expressed in adipose tissue and is a major regulator of insulin and glucose metabolism. In contrast, PPAR α is highly expressed in tissues displaying a high metabolic rate of fatty acids, such as the liver and skeletal muscle. PPAR α modulates intracellular lipid metabolism by transcriptional regulation of genes involved in fatty acid uptake, mitochondrial fatty acid oxidation and triglycerides catabolism. PPAR α is the molecular target of fibrates such as Gemfibrozil, etc.

Telmisartan acts as a partial PPAR α agonist and induces PPAR α expression. Thus there is induction of hepatic ACSL1 [acyl coA synthetase long chain] and CPT1A [carnitine palmitoyl transferase]. This causes significant decrease of triglyceride level. PPAR α in skeletal muscle is not affected by Telmisartan. Hence the myopathy associated with fibrates is not seen with Telmisartan. Thus PPAR α activation by Telmisartan is liver specific because of its specific pharmacokinetic Profile.

It is widely believed that the currently available ARBs are metabolically neutral and have little or no impact on carbohydrate and lipid metabolism when administered in conventional doses used to treat hypertension. However, the current findings suggest that Telmisartan might be an exception in this regard and provide insight into new strategies for developing molecules that could improve many if not all of the biochemical and blood pressure disturbances that compose the metabolic syndrome.

PPAR agonists convey beneficial effects as therapeutic agents for diabetes and atherosclerosis by lowering blood glucose, improving insulin resistance, inflammation, and lipid metabolism; however, adverse side effects limit their clinical use. As such, the future of PPAR-directed agents in cardio-metabolic therapy remains uncertain, although several late-stage molecules may still hold promise. Future directions in PPAR agonist development are likely to focus on optimizing the PPAR subtype interaction profile, maximizing the inhibition of PPAR- γ phosphorylation, and screening against off-target activity. At the present time, clinicians should

keep in mind the risk/benefit ratio of PPAR activators. Intensive research on this therapeutic target will likely lead to the development of safer and more effective PPAR agonists in the near future.

The multiple mechanisms of action of Telmisartan, including AT1 receptor blockade, PPAR γ modulation and hepatic PPAR α activation, characterizes this compound as a therapeutic option for the treatment of patients suffering from multiple cardio metabolic disorders such as hypertension, glucose intolerance, and dyslipidemia.

CONCLUSION:

Clinically, Telmisartan plays a major role in reducing the hypertension by blocking angiotension receptors. Now-a-days a large number of large scale clinical trials had proven that telmisartan not only reduces the blood pressure, but also it shows better improvement on most lipid indices, like increases in HDL and decreases in TC, TG, VLDL, and LDL. One of the possible explanations for such an improvement with telmisartan could be that it acts as a partial PPAR γ agonist. PPAR- γ regulates lipid metabolism and therefore reduces TG and LDL levels.

REFERENCES:

1. Barbara G. well, Joseph T. dipiro. Terry L. Schwinghammer, Lindy W. Hamilthon. Pharmacotherapy hand book. 6th edition. Mc Graw Hill Publishers;2008:99.
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension [ESH] and of the European Society of Cardiology [ESC]. *J Hypertens.* 2007;25[6]:1105–1187.
3. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. *JAMA.* 2003;289[18]:2363–2369.
4. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. *JAMA.* 2010;303[20]:2043–2050.
5. Heidenreich PA, Trogon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. *Circulation.* 2011;123[8]:933–944.
6. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. *Circulation.* 2011;125[1]:e2–e220.

7. Kannel WB: Hypertension as a risk factor for cardiac events: epidemiologic results of long-term studies. *J Cardiovasc Pharmacol* 1993; 21: 27-37.
8. Fedder DO, Koro CE, L'Italien GJ: New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid - Lowering Drug Therapy. *Circulation* 2002; 105:152-156.
9. Clinical Pharmacy and Therapeutics. Roger Walker, Cate Whittelesea. 5th edition. Churchill Livingstone Elsevier Publishers;2012:389.
10. Kannel WB: Hypertension as a risk factor for cardiac events: epidemiologic results of long-term studies. *J Cardiovasc Pharmacol* 1993; 21: 27-37.
11. Fedder DO, Koro CE, L'Italien GJ: New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid - Lowering Drug Therapy. *Circulation* 2002; 105:152-156.
12. Meredith PA: Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. *Am J Cardiovasc Drugs* 2005; 5: 171-183.
13. Schmieder RE, Hilgers KF, Schlaich MP, et al. Reninangiotensin system and cardiovascular risk. *Lancet.* 2007;369:1208–1219.
14. Norwood D, Branch E, Smith B et al. Olmesartan Medoxomil for Hypertension: A Clinical Review. *Drug Forecast.* 2002;27:12.
15. Wienen W, Entzeroth M, van Meel JCA, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. *Cardiovasc Drug Rev.* 2000;18:127–156.
16. Meredith P. Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. *Am J Cardiol* 1999;84:7K-12K.
17. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor [PPAR]. *J Biol Chem.* 1995; 270:12953–12956.
18. Guan Y, Breyer MD: Peroxisome proliferator-activated receptors [PPARs]: Novel therapeutic targets in renal disease. *Kidney Int.* 2001;60:14–30.
19. Fajas L, Debril MB, Auwerx J: Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis. *J Mol Endocrinol.* 2001;27: 1–9.
20. Desvergne B, Wahli W: Peroxisome proliferator-activated receptor: Nuclear control of metabolism. *Endocr Rev.* 1999;20: 649–688,
21. Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator- activated receptor gamma and metabolic disease. *Annu Rev Biochem.* 2001;70: 341–367.

22. Wang-Soo Lee¹ and Jaetaek Kim²; Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions: Volume 2015.
23. Ginsberg HN: Treatment for patients with the metabolic syndrome. *Am J Cardiol.* 2003; 91: 29E–39E.
24. Gurnell M, Savage DB, Chatterjee VK, O’Rahilly S: The metabolic syndrome: Peroxisome proliferator-activated receptor gamma and its therapeutic modulation. *J Clin Endocrinol Metab.* 2003;88: 2412–2421.
25. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C: Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation.* 1998;98: 2088–2093.
26. Jones AB: Peroxisome proliferator-activated receptor [PPAR] modulators: Diabetes and beyond. *Med Res Rev.* 2001;21: 540–552.
27. Guan Y, Zhang Y, Davis L, Breyer MD: Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. *Am J Physiol.* 1997; 273: F1013–F1022.
28. Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z: PPAR agonists protect mesangial cells from interleukin 1 α -induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. *J Am Soc Nephrol.* 2003;14:593–600.
29. Qi C, Zhu Y, Reddy JK: Peroxisome proliferator-activated receptors, coactivators, and downstream targets. *Cell Biochem Biophys.* 2000;32:187–204.
30. Bronfman, M., L. Amigo, and M. N. Morales. 1986. Activation of hypolipidemic drugs to acyl-coenzyme A thioesters. *Biochem. J.* 239:781–784.
31. Aarsland, A., and R. Berge. Peroxisome proliferating sulphur- and oxy-substituted fatty acid analogues are activated to acyl coenzyme A thioesters. *Biochem. Pharmacol.* 1990;41:53–61.
32. Skrede, S., M. Narce, S. Bergseth, and J. Bremer. The effects of alkylthioacetic acids [3-thia fatty acids] on fatty acid metabolism in isolated hepatocytes. *Biochim. Biophys. Acta.* 1989;1005: 296–302.
33. Maragandakis, M. E., and H. Hankin. On the mode of action of lipid lowering agents. V. Kinetics of the inhibition in vitro of rat acetyl-coA carboxylase. *J. biochem.* 1971:348–354.
34. Toussant, N. J., M. D. Wilson, and S. D. Clarke. Coordinate suppression of liver acetyl CoA carboxylase and fatty acid synthase by polyunsaturated fat. *J. Nutr.* 1981;111:146–163.
35. Asiedu, D. K., A. Al-Shurbaji, A. C. Rustan, I. Björkhem, and R. K. Berge. Hepatic fatty acid metabolism as a determinant of plasma and liver triacylglycerol levels. Studies on tetradecylthioacetic and tetradecylthiopropionic acids. *Eur. J. Biochem.* 1995;227: 715–722.
36. Blake, W. L., and S. D. Clarke. Suppression of rat hepatic fatty acid synthase and SREBP-1c transcription by dietary polyunsaturated fat. *Nutr.* 1990;120:1727–1729.
37. Rustan, A. C., E. N. Christiansen, and C. A. Drevor. Serum lipids, hepatic glycerolipid metabolism and peroxisomal fatty acid oxidation in rats fed omega-3 and omega-6 fatty acids. *Biochem. J.* 1992;283:333–339.
38. Calderon, B., R. Hertz, and J. Bar-Tam. Tissue selective modulation of redox and phosphate potentials by beta, beta'-methyl-substituted hexadecanedioic acid. *Endocrinology.* 1992;131: 1629–1635.
39. Skrede, S., J. Bremer, R. K. Berge, and A. C. Rustan. Stimulation of fatty acid oxidation by a 3-thia fatty acid reduces triacylglycerol secretion in cultured rat hepatocytes. *J. Lipid Res.* 1994.35:1395–1404.
40. Bar-Tana, J., G. Rose-Kahn, B. Frenkel, Z. Shafer, and M. Fainaru. Hypolipidaemic effect of beta, beta'-methyl-substituted hexadecanedioic acid [MEDICA 16] in normal and nephrotic rats. *J. Lipid Res.* 1988.29:431–441.
41. Markus Clemenz, Nilolaj Frost, Michael Schupp, Sandrine Caron, Anna Foryst Ludwig, Christian Bohm. American Diabetes Association. July 2009; 58[7]. doi: 10.2337/db07-0839.
42. Jutta M. Nagel, Anne B. Tietz, Burkhard Gfke, Klaus G. Parhofer. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. *Meta Clin Exp.* 2006;55:1149–1154.
43. Derosa G, Cicero AF, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. *Clin Ther* 2004;26:1228–1236.
44. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. *Hypertens Res.* 2004;27:457–464.
45. Koulouris S, Symeonides P, Triantafyllou K, et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-

density lipoprotein cholesterol in patients with type 2 diabetes mellitus. *Am J Cardiol* 2005;95:1386-1388.

46. Akiko Aoki, Tetsuya Ogawa, Hiroyuki Sumino, et al. Long term effects of telmisartan on blood pressure, the rennin-angiotensin-aldosterone system, and lipids in hypertensive patients. *Heart Vessels*.2010;25:195-202.

47. Ganesh Dakhale, Anoop Salve, Mrunalini Hardas, Mohini Mahatme, Sachin Hiware and Abhijit Shinde. Clinical efficacy and safety of telmisartan versus losartan and their effect on lipid profile in stage 1 hypertension: A randomized, double blind, 12 week trial. *IJPR* 2015;5[4]:80-85.

48. Willa Hsueh, Giora Davidai, Robert Henry, Sunder Mudaliar. Telmisartan Effects on Insulin Resistance in Obese or Overweight Adults Without Diabetes or Hypertension. 2010; 12[9]: 746-752.

49. Kazutoshi Murakami, Jun Wad, Daisuke Ogawa, Chikage Sato Horiguchi, Tomoko Miyoshi, Motofumi Sasaki, Haruhito A Uchida, Yoshio Nakamura and Hirofumi Makino. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama. *Diabetes & Vascular Disease Research*.2012;10[1]:93-96.

50. Vanessa Souza-Mello, Bianca M. Greg Orio, Fernando S. Cardoso-De-Lemos, LaIs De Carvalho, M Arcia B. Aguila and Carlos A. Mandarin-De-Lacerda. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. *Clinical Science*. 2010;119:239-250.

51. Manish Kumar, Anuj Kumar Pathak, Pramod Kumar Manjhi, Lalit Mohan, Harihar Dikshit. Study of changes in serum lipid profile and blood sugar level by perindopril and telmisartan during treatment of systemic hypertension. *IJBCP*. 2014;3[3]:454-459.

52. Scott S Billecke, Pamela A Marcovitz. Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension. *Vascular Health and Risk Management*. 2013;9:95-104.

53. Stephen C. Benson, Harrihar A. Pershadsingh, Christopher I. Ho, Amar Chittiboyina, Prashant Desai, et al. Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR γ -Modulating Activity. *AHA*. 2004;43:993-1002.

54. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the

metabolic syndrome in a prospective cohort study. *Am J Epidemiol*. 2002;156:1070-1077.

55. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. *J Int Med Res*. 2000;28:149-167.

56. R. Negro, G. Formoso and H. Hassan. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. *J Endocrinol Invest*. 2006;29:957-961.

57. Pengli Zhu, Hong Lin, Chengai Sun, Fan Lin, Huizhen Yu, Xiuping Zhuo, Chanjuan Zhou And Zhisheng Deng. Synergistic effects of telmisartan and pyridoxamine on early renal damage in spontaneously hypertensive rats. *Mol Medi Reports*. 2012;5: 655-662.

58. Shingo Maeda, Mitsuhiro Nishizaki, Noriyoshi Yamawake, Takashi Ashikaga, Kensuke Ihara, Tadashi Murai, Hiroyuki Fujii, Harumizu Sakurada, Masayasu Hiraoka, Mitsuaki Isobe. Effect of High-dose Telmisartan on the Prevention of Recurrent Atrial Fibrillation in Hypertensive Patients. *J of Atrial Fibr*. 2010;3[3]:11-19.

59. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. *J Clin Pharmacol* 2000;40:1380-1390.

60. Fogari R, Derosa G, Zoppi A, Preti P, Lazzari P, Destro M, Fogari E, Rinaldi A, Mugellini A. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. *Am J Hypertens* 2007;20:417-422.

61. Mary Girgis Shahataa, Gomaa Mostafa-Hedeab, Esam Fouaad Ali, Emad ahmed Mahdi, Fatma Abd Elhaleem Mahmoud. Effects of Telmisartan and Pioglitazone on High Fructose Induced Metabolic Syndrome in Rats. *Canadian J of Physio and Pharmacol*. 2016.

62. D. Lalitha Devi, D. Arthi and K.S.N. Murthy. Effects of Telmisartan on Weight gain and Obesity in patients ith Essential Hypertension and Metabolic Syndrome. *Int J of Cur Medic and Pharma Res*. 2017;3[5]:1758-1762.

63. Yoshiki Murayama, Toshihiko Ishimitsu, Masahito Furuichi, Yasuhiko Ueno, Hiroshi Satonaka. Comparison between High-dose Telmisartan and Fixed dose Combination of Telmisartan and

64. Hydrochlorothiazide in Patients with Hypertension. *Dokkyo Journal of Medical Science*. *Dokkyo J of Med Sci*. 2016;2:115-123.

65. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ -modulating activity. *Hypertension*. 2004;243:993-1002.
66. Shatha M. Al-Safi, Najah R. Al-Mousawi. A study of the effects Telmisartan on induced hyperlipidemia and atherosclerosis in male rabbits. *Kufa J for Vete Medic Sci*. 2010;1[1]:188-200.
67. Cristiana Vitale, Giuseppe Mercuro, Carlotta Castiglioni, Alessandra Cornoldi†1, Arianna Tulli, Massimo Fini, Maurizio Volterrani and Giuseppe MC Rosano. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. *Cardiovascular Diabetology* 2005; 4[6].
68. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA*. 2002;288:2709-2716.
69. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ -modulating activity. *Hypertension*. 2004;43:993-1002.
70. Yagnik Bhalodia, Navin Sheth, Jitendra Vaghasiya and Nurudin Jivani. Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury. *Renal Failure*. 2010;32[9]: 1088–1094.
71. Angelo Zinellu, Salvatore Sotgia, Arduino A.Mangoni, Elisabetta Sotgiu, Sara Ena, Dionigia Arru, Stefano Assaretti, Angela Baralla, Andrea E. Satta and Ciriaco Carru. Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease. *Disease markers*. 2016.
72. Vanitha M, Vijayal k. Effect of telmisartan on serum lipid profile in patients with hypertension and dyslipidemia. *IJMRHS*. 2013;2[4]:745-749.
73. T. Inoue, T. Morooka, K. Moroe, H. Ikeda, K. Node. Effect of telmisartan on cholesterol levels in patients with hypertension- Saga Telmisartan Aggressive Research [STAR]. *Horm Metab Res*. 2007;39:372-376.
74. Geun Joo Choi, Hyun Min Kim, Hyun Kang and Jaetaek Kim. Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. *Cur Med Res and Opin*. 2016;32[7].
75. Giuseppe Derosa, Pietro D. Ragonesi, Amedo Mugellini, Leonardina Ciccarelli and Roberto Fogari. Effects of Telmisartan Compared with Eprosartan on Blood Pressure Control, Glucose Metabolism and Lipid Profile in Hypertension, Type-2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled 12-Month Study. *Hypertens Res*. 2004;27[7]:457-464.